Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BullFrog AI Holdings, Inc.BFRG · Entity 8036 | Director | June 11, 2026 | June 15, 2026 |
| CapForce Inc.OPGN · Entity 9776 | Director | June 07, 2023 | June 09, 2023 |
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | CFO, Treasurer & Secretary | February 08, 2021 | February 10, 2021 |
| REGENERX BIOPHARMACEUTICALS INCRGRX · Entity 111578 | Director | May 17, 2022 | May 19, 2022 |
| Senseonics Holdings, Inc.SENS · Entity 5469 | CFO, Secretary and Treasurer | February 02, 2018 | February 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BullFrog AI Holdings, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 | Direct | 15,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,000 · Balance 15,000 F3: The options were issued as a grant under the Plan, based on the market price on the date of the grant. F1: Represents stock options issued under BullFrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), which vest on June 11, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing, which may, or may not, constitute a change in control. F2: The stock options expire on June 12, 2036. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options issued under BullFrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), which vest on June 11, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing, which may, or may not, constitute a change in control.
F2: The stock options expire on June 12, 2036.
F3: The options were issued as a grant under the Plan, based on the market price on the date of the grant.
CapForce Inc.
Report date June 07, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,075 |
Reported balance
After 2023-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-07 · Grant · Acquired 1,500 · Balance 3,075 F1: Represents an award of restricted stock units vesting on the first anniversary of the date of grant, or if earlier, the date of the 2024 annual meeting of stockholders, subject to acceleration and vesting if the director leaves the Board of Directors in connection with a change in control of OpGen, Inc. (the "Company"). F2: The number of restricted stock units and shares reflects the application of the twenty-for-one reverse stock split effected by the Company on January 5, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units vesting on the first anniversary of the date of grant, or if earlier, the date of the 2024 annual meeting of stockholders, subject to acceleration and vesting if the director leaves the Board of Directors in connection with a change in control of OpGen, Inc. (the "Company").
F2: The number of restricted stock units and shares reflects the application of the twenty-for-one reverse stock split effected by the Company on January 5, 2023.
Lyra Therapeutics, Inc.
Report date February 08, 2021 · Filed February 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.63 · Expires 2031-02-07 | Direct | 45,000 |
Reported balance
After 2021-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-08 · Grant · Acquired 45,000 · Balance 45,000 F1: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following February 8, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following February 8, 2021.
REGENERX BIOPHARMACEUTICALS INC
Report date May 17, 2022 · Filed May 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2032-05-17 | Direct | 290,000 |
Reported balance
After 2022-05-17 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-05-17 · Grant · Acquired 290,000 · Balance 290,000 F4: 145,000 shares vest on each of 5/17/22 and 5/17/23. |
| Common StockSEC Table I · non-derivative | Direct | 104,456 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 104,456 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2022-06-30 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 100,000 F1: 100% vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2023-03-16 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 100,000 F1: 100% vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2027-09-01 | Direct | 125,000 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 125,000 F1: 100% vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2028-07-17 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 200,000 F1: 100% vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2029-05-15 | Direct | 250,000 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 250,000 F1: 100% vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2030-06-10 | Direct | 250,000 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 250,000 F2: 62,500 shares vest on each of 6/10/20, 6/10/21, 6/10/22 and 6/10/23. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2031-08-02 | Direct | 290,000 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 290,000 F3: 72,500 shares vest on each of 8/2/21, 8/2/22, 8/2/23 and 8/2/24. |
| Convertible Promissory Note (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.12 · Expires 2024-02-27 | Direct | 15,625 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 15,625 |
| Convertible Promissory Note (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.12 · Expires 2024-05-13 | Direct | 15,625 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 15,625 |
| Common Stock Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2024-02-27 | Direct | 0 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 0 |
| Common Stock Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2024-05-13 | Direct | 0 |
Reported balance
Holding disclosure · report date 2022-05-17 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: 100% vested.
F2: 62,500 shares vest on each of 6/10/20, 6/10/21, 6/10/22 and 6/10/23.
F3: 72,500 shares vest on each of 8/2/21, 8/2/22, 8/2/23 and 8/2/24.
F4: 145,000 shares vest on each of 5/17/22 and 5/17/23.
Senseonics Holdings, Inc.
Report date February 02, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.62 · Expires 2028-02-01 | Direct | 392,999 |
Reported balance
After 2018-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-02 · Grant · Acquired 392,999 · Balance 392,999 F1: Shares vest monthly over four years subject to the reporting person's continuous service with the issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares vest monthly over four years subject to the reporting person's continuous service with the issuer as of the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:29 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001493152-26-028742 · ownership.xml · derivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · price: The options were issued as a grant under the Plan, based on the market price on the date of the grant. F1 · derivative.exercise_date: Represents stock options issued under BullFrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), which vest on June 11, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing, which may, or may not, constitute a change in control. F2 · derivative.expiration_date: The stock options expire on June 12, 2036. Read SEC document |
| September 25, 2025 Filed Sep 30, 2025 00:12 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001493152-25-016097 · ownership.xml · derivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · price: The options were issued as a grant under the Plan, based on the market price on the date of the grant. F1 · derivative.exercise_date: Represents stock options issued under Bullfrog AI Holdings, Inc.'s (the "Company") 2022 Equity Compensation Plan, as amended from time to time (the "Plan"), vesting on the earlier of September 25, 2026 and the date of the Company's annual meeting for fiscal year 2026. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing which may, or may not, constitute a change in control. F2 · derivative.expiration_date: The stock options expire on September 25, 2035. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 20:05 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-025525 · ownership.xml · nonDerivative · entry 2 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,523 F2 · shares: Represents 2,813 shares of Common Stock issued as an equity grant under the Plan, fully vested upon grant. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 20:05 UTC | BullFrog AI Holdings, Inc. BFRG · Entity 8036 | GrantCommon Stock | 5,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-025525 · ownership.xml · nonDerivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,710 F1 · shares: Represents Restricted Stock Units ("RSUs") issued under the Company's 2022 Equity Compensation Plan (the "Plan"), vesting 50% on September 1, 2026, and the remaining 50% on September 1, 2027. Lapse of forfeiture restrictions will accelerate upon a change in control of the Company (as defined in the Plan) or a significant financing which may, or may not, constitute a change in control. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| September 26, 2024 Filed Feb 12, 2025 14:00 UTC | BullFrog AI Holdings, Inc. BFRG,BFRGW · Entity 8036 | GrantStock options (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001493152-25-006047 · ownership.xml · derivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common stock · 15,000 shares Expires not disclosed F1 · deemedExecutionDate: The options vest on September 26, 2025. F3 · price: The options were issued as a grant under the Company's equity incentive plan based on the market price on the date of the grant. F1 · derivative.exercise_date: The options vest on September 26, 2025. F2 · derivative.expiration_date: The options expire on September 26, 2034. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:32 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-23-000850 · ownership.xml · nonDerivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,075 F1 · security: Represents an award of restricted stock units vesting on the first anniversary of the date of grant, or if earlier, the date of the 2024 annual meeting of stockholders, subject to acceleration and vesting if the director leaves the Board of Directors in connection with a change in control of OpGen, Inc. (the "Company"). F2 · balance_after: The number of restricted stock units and shares reflects the application of the twenty-for-one reverse stock split effected by the Company on January 5, 2023. Read SEC document |
| April 16, 2023 Filed Apr 18, 2023 21:45 UTC | BullFrog AI Holdings, Inc. BFRG,BFRGW · Entity 8036 | GrantStock options (Right to buy) · Derivative | 40,000 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001493152-23-012818 · ownership.xml · derivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires not disclosed F1 · deemedExecutionDate: The options vest as follows: 8,888 options were deemed immediately vested and, each month thereafter 864 shares vest per month. F1 · derivative.exercise_date: The options vest as follows: 8,888 options were deemed immediately vested and, each month thereafter 864 shares vest per month. F2 · derivative.expiration_date: The option expires on April 16, 2028. Read SEC document |
| April 16, 2023 Filed May 9, 2023 20:15 UTC Amendment | BullFrog AI Holdings, Inc. BFRG,BFRGW · Entity 8036 | GrantStock options (Right to buy) · Derivative | 40,000 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001493152-23-015943 · ownership.xml · derivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires not disclosed F1 · deemedExecutionDate: The options vest as follows: 8,888 options were deemed immediately vested and, each month thereafter 864 shares vest per month. F1 · derivative.exercise_date: The options vest as follows: 8,888 options were deemed immediately vested and, each month thereafter 864 shares vest per month. F2 · derivative.expiration_date: Amendment: The option expires on April 16, 2033. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:36 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-22-000771 · ownership.xml · nonDerivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 F1 · security: Represents an award of restricted stock units vesting on the first anniversary of the date of grant, or if earlier, the date of the 2023 annual meeting of stockholders, subject to acceleration and vesting if the director leaves the Board of Directors in connection with a change in control of the Company. F2 · balance_after: The number of restricted stock units and shares reflects the application of the twenty-for-one reverse stock split effected by OpGen, Inc. on August 28, 2019 to 30,000 restricted stock units and shares of common stock held by the reporting person as of such date. Read SEC document |
| May 17, 2022 Filed May 19, 2022 17:08 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | GrantStock Option (Right to Buy) · Derivative | 290,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001437749-22-013090 · rdgdoc.xml · derivative · entry 13 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2032-05-17 F4 · derivative.exercise_date: 145,000 shares vest on each of 5/17/22 and 5/17/23. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 16:09 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | GrantStock Option (right to buy) · Derivative | 290,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0000914190-21-000205 · edgar.xml · derivative · entry 13 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2031-08-02 F4 · derivative.exercise_date: 72,500 shares vest on each of 8/2/21, 8/2/22, 8/2/23 and 8/2/24. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 22:33 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-21-000506 · ownership.xml · nonDerivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · security: Represents an award of restricted stock units vesting on the first anniversary of the date of grant, or if earlier, the date of the 2022 annual meeting of stockholders, subject to acceleration and vesting if the director leaves the Board of Directors in connection with a change in control of the ompany. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:05 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 45,000 | $0.00 Strike: $10.63 | $0.00 |
DisclosureSEC source: 0000899243-21-005659 · doc4.xml · derivative · entry 1 Elsey R Don · CIK 0001380742 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-02-07 F1 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following February 8, 2021. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 21:38 UTC | CapForce Inc. OPGN · Entity 9776 | GrantStock Option Award · Derivative | 50,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001079973-20-000841 · ownership.xml · derivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: The grant of stock options have a one-year vesting schedule, vesting quarterly in equal installments on the first day of each three month period, as long as the Reporting Person continues providing services to the Company on each such vesting date. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 18:11 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000914190-20-000216 · edgar.xml · derivative · entry 9 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-06-10 F5 · derivative.exercise_date: 62,500 shares vest on each of 6/10/20, 6/10/21, 6/10/22 and 6/10/23. Read SEC document |
| April 30, 2020 Filed May 1, 2020 22:34 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 20,635 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011745 · doc4.xml · derivative · entry 1 Elsey R Don · CIK 0001380742 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,635 Underlying: Common Stock · 20,635 shares Expires 2030-04-29 F1 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following April 30, 2020. Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:04 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0000914190-19-000162 · edgar.xml · derivative · entry 9 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-05-15 F4 · derivative.exercise_date: 62,500 shares vest on each of 5/15/19, 5/15/20, 5/15/21 and 5/15/22. Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:52 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 15,625 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0000914190-19-000147 · edgar.xml · derivative · entry 12 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2024-05-13 Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:52 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | PurchaseConvertible Promissory Note (right to buy) · Derivative | Not disclosed | $2,500.00 Strike: $0.12 | $2,500.00 |
DisclosureSEC source: 0000914190-19-000147 · edgar.xml · derivative · entry 11 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 20,833 shares Expires 2024-05-13 Read SEC document |
| May 01, 2019 Filed May 2, 2019 17:24 UTC | CapForce Inc. OPGN · Entity 9776 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-19-000256 · ownership.xml · nonDerivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · security: Represents an award of restricted stock units vesting in three equal installments on the first three anniversaries of the date of grant. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:45 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 15,625 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0000914190-19-000063 · edgar.xml · derivative · entry 10 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2024-02-27 Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:45 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | PurchaseConvertible Promissory Note (right to buy) · Derivative | Not disclosed | $2,500.00 Strike: $0.12 | $2,500.00 |
DisclosureSEC source: 0000914190-19-000063 · edgar.xml · derivative · entry 9 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 20,833 shares Expires 2024-02-27 Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 17:27 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | ConversionConvertible Promissory Note (right to buy) · Derivative | 104,456 | Not disclosed Strike: $0.06 | Not disclosed |
DisclosureSEC source: 0000914190-18-000402 · edgar.xml · derivative · entry 2 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,456 shares Expires 2018-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Convertible Promissory Note in the principal amount of $5,000 accrued $1,267.36 in interest and both principal and interest were converted into 104,456 shares of common stock at a conversion price of $0.06 per share. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 17:27 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | ConversionCommon Stock | 104,456 | $0.06 | $6,267.36 |
DisclosureSEC source: 0000914190-18-000402 · edgar.xml · nonDerivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 17:11 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.21 Strike: $0.21 | $42,000.00 |
DisclosureSEC source: 0000914190-18-000295 · edgar.xml · derivative · entry 2 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 200,000 shares Expires 2028-07-17 F2 · derivative.exercise_date: The option vests in four equal installments of 50,000 shares on each of July 17, 2018, 2019, 2020 and 2021. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 23:30 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantStock Option (right to buy) · Derivative | 392,999 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-18-007643 · doc4.xml · derivative · entry 1 Elsey R Don · CIK 0001380742 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,999 Underlying: Common Stock · 392,999 shares Expires 2028-02-01 F1 · derivative.exercise_date: Shares vest monthly over four years subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 16:16 UTC | REGENERX BIOPHARMACEUTICALS INC RGRX · Entity 111578 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0000914190-17-000272 · edgar.xml · derivative · entry 1 Elsey R Don · CIK 0001380742 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-09-01 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on September 1, 2017. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 22:21 UTC | Senseonics Holdings, Inc. SENS · Entity 5469 | GrantStock Option (right to buy) · Derivative | 313,391 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-17-004603 · doc4.xml · derivative · entry 1 Elsey R Don · CIK 0001380742 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,391 Underlying: Common Stock · 313,391 shares Expires 2027-01-16 F1 · derivative.exercise_date: Shares vest monthly over four years subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.